

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2021

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £35.

DISEASE / DISORDER	Price (£)	Routine TAT (Calendar days)	Gene(s) or locus	Description of test <i>(including reference intervals/ clinical decision values where applicable)</i>	Category
<b>CYTOGENETIC TESTS</b>					
<u>Fetal loss referrals:</u> Common aneuploidy testing <b>R22.1, R318.1</b> Array CGH <b>R22.2, R318.2</b> Karyotype <b>R297.1</b> FISH DNA storage		42 42 42 42 N/A	Chr 13, 18, 21, X, Y Genome-wide CNVs  Targeted probe	QF PCR Array CGH G banding FISH	
<u>Postnatal cytogenetic referrals:</u> Common aneuploidy testing <b>R26.1</b> Array CGH (multiple indications) Targeted follow up testing <b>R375.1</b> Karyotype <b>R297.1</b> FISH		3 <sup>1</sup> /42 42 42 42 42 <sup>1</sup> urgent neonates		QF PCR Array CGH Array or FISH G banding FISH	
<b>MOLECULAR GENETIC TESTS</b>					
Albinism or congenital nystagmus <b>R39</b>		84	23-gene panel	Next-generation sequencing	NGS service
<i>TYR</i> and <i>OCA2</i> dosage analysis*		42	<i>TYR, OCA2</i>	MLPA	Targeted mutation test
Albright hereditary osteodystrophy, pseudohypoparathyroidism and pseudopseudohypoparathyroidism Methylation testing <b>R293.2</b>		42	<i>GNAS</i>	MS-MLPA	Imprinting analysis

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2021

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £35.

UPD(20) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
<i>GNAS</i> sequencing <b>R293.1</b>		42	<i>GNAS</i>	NGS + Sanger sequencing	Single gene screen
Alpha 1 - antitrypsin deficiency <b>R191</b>		42	<i>SERPINA1</i>	2 common mutations (S & Z)	Targeted mutation test
Angelman syndrome <b>R47</b> Chromosome 15 abnormalities		42	<i>SNURF:TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(15) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Aortopathy panel	See Thoracic aortic aneurysm or dissection				
Beckwith-Wiedemann syndrome <b>R49</b> ; isolated hemihypertrophy or macroglossia <b>R50</b> Chromosome 11 abnormalities		42	ICR1 and ICR2	MS-MLPA	Imprinting analysis
UPD(11) follow-up <b>R263</b>		42	11p15.5	Microsatellite analysis	
<i>CDKN1C</i> sequencing <b>R49.3</b>		42	<i>CDKN1C</i>	Sanger sequencing	Single gene screen
Blepharophimosis, ptosis and epicanthus inversus (BPES) <b>R43</b>		42	<i>FOXL2</i>	Full mutation screen + MLPA + fragment analysis	Single gene screen
Breast/ovarian cancer	See Inherited breast cancer and ovarian cancer				
Ovarian cancer	See Inherited ovarian cancer (without breast cancer)				
Chronic myeloid leukaemia (CML)	See separate Oncology service list (on Oncology genetics page of our website)				
Chronic lymphoblastic leukaemia (CLL)	See separate Oncology service list (on Oncology genetics page of our website)				
Cowden syndrome	See <i>PTEN</i> hamartoma tumour syndrome				
Cystic fibrosis Routine diagnostic or carrier testing <b>R184.1, R185.1</b>		42	<i>CFTR</i>	50 most common UK mutations	Targeted mutation test
Urgent carrier testing <b>R185.1</b>		14	<i>CFTR</i>	50 most common UK mutations	

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2021

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £35.

Newborn screen from blood spots <b>R253</b>		4 working days	<i>CFTR</i>	4 most common mutations in the UK	
Factor V Leiden and Prothrombin mutations*		42	<i>F5, F2</i>	NGS genotyping	Targeted mutation test
Familial testing for known variants Predictive testing <b>R242</b> Carrier testing <b>R244</b> Parental/segregation testing <b>R375</b>	<i>Please send to appropriate specialist laboratory for the familial condition</i>				Targeted mutation test
Fragile X syndrome (FRAXA) <b>R29.3, R53</b> or Premature ovarian insufficiency (POI) <b>R402.2</b> Standard fluorescent PCR		42	<i>FMR1</i>	Expand™ long-template PCR kit	Repeat expansion test
Amplidex™ PCR		42	<i>FMR1</i>	Amplidex™ <i>FMR1</i> PCR kit (Normal: up to 45 repeats; Intermediate: 46-58 repeats; Premutation: 59-200 repeats; Full mutation: >200 repeats)	
Haematological malignancies	<i>See separate Oncology service list (on Oncology genetics page of our website)</i>				
Haemochromatosis	<i>See Iron overload – hereditary haemochromatosis testing</i>				
Hypogonadotropic hypogonadism <b>R148</b> 14-gene panel		84	14-gene panel	Next-generation sequencing	NGS service
Inherited breast cancer and ovarian cancer <b>R208</b>		42	<i>BRCA1, BRCA2, PALB2</i>	Next-generation sequencing + MLPA for <i>BRCA1</i> and <i>BRCA2</i>	NGS service
Inherited ovarian cancer (without breast cancer) <b>R207</b>		42	8-gene panel	Next-generation sequencing + MLPA for <i>BRCA1</i> and <i>BRCA2</i>	NGS service
Iron overload – hereditary haemochromatosis testing <b>R95</b>		42	<i>HFE</i>	Two common mutations	Targeted mutation test
Kagami-Ogata syndrome <b>R268</b> Methylation abnormalities		42	<i>MEG3:TSS-DMR</i>	Methylation-sensitive MLPA	Imprinting analysis

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2021

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £35.

Paternal UPD(14) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Kallmann syndrome	See Hypogonadotropic hypogonadism				
Marfan syndrome	See Thoracic aortic aneurysm or dissection				
Multi-locus imprinting disorder*		42	No specific gene	Methylation-sensitive MLPA for chromosomes 6, 7, 11, 14, 15 and 20	Imprinting analysis
Myeloproliferative neoplasia (MPN)	See separate Oncology service list (on Oncology genetics page of our website)				
Neurofibromatosis type 1 (NF1) <b>R222</b> including Legius syndrome*		42	<i>NF1, SPRED1</i>	Next-generation sequencing + MLPA for <i>NF1</i>	NGS service
Noonan syndrome*					
Full screen		84	14-gene panel	Next-generation sequencing	NGS service
Data analysis only		84	14-gene panel	Next-generation sequencing (data)	
Oculopharyngeal muscular dystrophy (OPMD) <b>R75</b>		42	<i>PABPN1</i>	Fluorescent PCR (Normal: 10 repeats; Pathogenic: 11-17 repeats)	Repeat expansion test
Prader-Willi syndrome <b>R48</b> Chromosome 15 abnormalities		42	<i>SNURF:TSS-DMR</i>	MS-MLPA	Imprinting analysis
UPD(15) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Premature ovarian failure (POF) / Primary ovarian insufficiency (POI), Fragile X-related	See Fragile X syndrome				
Prenatal testing for known pathogenic variants*	Please send to appropriate specialist laboratory for the familial condition				Targeted mutation test
Primary ciliary dyskinesia (PCD)	See Respiratory ciliopathies				
Pseudohypoparathyroidism (PHP)	See Albright hereditary osteodystrophy				
<i>PTEN</i> hamartoma tumour syndrome <b>R213</b>		42	<i>PTEN</i>	Mutation screening by NGS + MLPA	NGS service
Respiratory ciliopathies including non-CF bronchiectasis <b>R189</b>		84	46-gene panel	Next-generation sequencing	NGS service

## WESSEX REGIONAL GENETICS LABORATORY – RARE DISEASE TESTS – SERVICE LIST – from 1<sup>st</sup> April 2021

**Note:** NHS referrals in England are funded directly by NHS England and are subject to the National Genomic Test Directory; referral criteria must satisfy the NHSE Rare and Inherited Disease eligibility criteria. Test Directory indications are in **bold**. Tests not currently covered by the Test Directory are marked with an asterisk\*. Non-NHSE, private and overseas referrals will be invoiced. Samples received in error or with inadequate material for testing will be charged at £35.

RNA studies (investigating the effect of sequence variants on splicing) <b>R296</b>		42	No specific gene	Analysis of DNA variants for splicing abnormalities	Specialised testing
Rubinstein-Taybi syndrome*		42	<i>CREBBP, EP300</i>	Next-generation sequencing + MLPA	NGS service
Russell-Silver syndrome	<i>See Silver-Russell syndrome</i>				
Sequencing of known variants (confirmations, family or predictive testing)	<i>Please send to appropriate specialist laboratory for the familial condition</i>				Targeted mutation test
Silver-Russell syndrome (Growth failure in early childhood) <b>R147.2</b> Chromosome 11 abnormalities		42	ICR1 only	MS-MLPA	Imprinting analysis
UPD(7) by MS-MLPA		42	No specific gene	MS-MLPA	
UPD(11) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Thoracic aortic aneurysm or dissection (TAAD) <b>R125</b>		84	32-gene panel	Next-generation sequencing + MLPA for <i>FBN1</i> only	NGS service
Temple syndrome <b>R267</b> Methylation abnormalities		42	<i>MEG3:TSS-DMR</i>	MS-MLPA	Imprinting analysis
Maternal UPD(14) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Transient neonatal diabetes mellitus (TNDM) (6q24-related neonatal diabetes, <b>R143.3</b> )		42	<i>PLAGL1:alt-TSS-DMR</i>	6q24 methylation, UPD and dosage analysis by MLPA	Imprinting analysis
UPD(6) follow-up <b>R263</b>		42	No specific gene	Microsatellite analysis	
Uniparental disomy confirmation <b>R263</b> (where no prior imprinting analysis at WRGL)		42	No specific gene	Microsatellite analysis	UPD confirmation
X-inactivation studies <b>R111</b>		42	No specific gene	Methylation analysis by restriction enzyme digestion ( <i>Random = &lt;80:20 ratio; skewed = &gt;91:9 ratio</i> ).	Specialised testing